Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/1078-0432.CCR-15-1961 http://scihub22266oqcxt.onion/10.1158/1078-0432.CCR-15-1961 C5502354!5502354!26842238     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Cancer+Res 2016 ; 22 (10): 2323-8 Nephropedia Template TP {{tp|p=26842238|t=2016. The Role of Neoadjuvant Trials in Drug Development for Solid Tumors |pdf=|usr=}}{{26842238}} gab.com Text The Role of Neoadjuvant Trials in Drug Development for Solid Tumors JO: Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=26842238 #FOAvip The relatively low success rate of phase II oncology trials in predicting success of novel drugs in phase III trials and in gaining regulatory approval may be due to reliance on the endpoint of response rate defined by the RECIST. The neoadjuvant treatment paradigm allows the antitumor activity of a novel therapy to be determined on a pathologic basis at the time of surgery instead of by RECIST, which was not developed to guide clinical decision making or correlate with long-term outcomes. Indeed, the FDA endorsed pathologic complete response (pCR) as a surrogate for overall survival (OS) in early-stage breast cancer and granted accelerated approval to pertuzumab based on this endpoint. We propose that pCR is a biologically rational method of determining treatment effect that may be more likely to predict OS. We discuss some advantages of the neoadjuvant trial design, review the use of neoadjuvant therapy as standards of care, and consider the neoadjuvant platform as a method for drug development. Twit Text FOAVip The Role of Neoadjuvant Trials in Drug Development for Solid Tumors ????Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=26842238 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26842238 #FOAvip English Wikipedia <ref>{{Cite pmid|26842238}}</ref> The Role of Neoadjuvant Trials in Drug Development for Solid Tumors #MMPMID26842238 Funt SA; Chapman PB Clin Cancer Res 2016[May]; 22 (10): 2323-8 PMID26842238show ga The relatively low success rate of phase II oncology trials in predicting success of novel drugs in phase III trials and in gaining regulatory approval may be due to reliance on the endpoint of response rate defined by the RECIST. The neoadjuvant treatment paradigm allows the antitumor activity of a novel therapy to be determined on a pathologic basis at the time of surgery instead of by RECIST, which was not developed to guide clinical decision making or correlate with long-term outcomes. Indeed, the FDA endorsed pathologic complete response (pCR) as a surrogate for overall survival (OS) in early-stage breast cancer and granted accelerated approval to pertuzumab based on this endpoint. We propose that pCR is a biologically rational method of determining treatment effect that may be more likely to predict OS. We discuss some advantages of the neoadjuvant trial design, review the use of neoadjuvant therapy as standards of care, and consider the neoadjuvant platform as a method for drug development. äThe Role of Neoadjuvant Trials in Drug Development for Solid Tumors (epmc).pdf DeepDyve Pubget Overpricing